| Bioactivity | Tabalumab (LY2127399) is a humanised anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus[1]. |
| Target | BAFF. |
| Invitro | Tabalumab (1-100 ng/mL; 44 h) neutralizes soluble and membrane-bound BaFF both in T1165.17 cells and (1 µg/mL; 3 days) CD19+ B-cells[1].Tabalumab (50 µg/mL; 15 min) inhibits BaFF binding to BR3, TacI, and BcMa in HEK293 cells[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Tabalumab (500 µg/rat; s.c.; single) leads to decreased B-cells and a reduction in non-canonical nF-κB signaling[1]. Animal Model: |
| Name | Tabalumab |
| CAS | 1143503-67-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Manetta J, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014 Aug 20;7:121-31. |